WCN26-7213 Evaluation of Renal Outcomes in IgA Nephropathy Patients in the National Kidney and Transplant Institute receiving SGLT2 Inhibitor Treatment versus Standard Care—A Retrospective Study

Read full text Summarise with VIRAT
Authors: Willianne Roselle Gutierrez, Anthony Rusell Villanueva
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) is an inflammatory renal disorder marked by the accumulation of IgA in the glomerular mesangium and is the most frequently documented primary glomerulonephritis globally. The standard treatment protocol for individuals with IgA nephropathy includes using supportive measures such as lifestyle intervention, medications inhibiting renin-angiotensin-aldosterone system (RAAS), fish oil, with or without any immunosuppressive agents like steroids, azathioprine, mycophenolate mofetil, cyclophosphamide, or rituximab.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106037–106037
Publication date
25 March 2026
Language
EN